.png "Atricure (NASDAQ: ATRC)")
BTIG analyst Sean Lavin maintained a Hold rating on Atricure (NASDAQ: ATRC) yesterday. The company’s shares closed yesterday at $27.99.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 16.4% and a 63.7% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Tactile Systems Technology, and Obalon Therapeutics Inc.
Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $30.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $30.96 and a one-year low of $14.88. Currently, Atricure has an average volume of 195.2K.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. Last month, Elizabeth Krell, a Director at ATRC sold 10,000 shares for a total of $228,200.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AtriCure, Inc. engages provision of treatment of atrial fibrillation and left atrial appendage. It operates through the following geographical segments: United States, Europe, Asia, and Other International.
